Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, ADC Therapeutics SA reported revenue of $81M, up 14.9% year over year. Operating margin was -149.3% and net margin -175.3%, on a free-cash-flow margin of -173.8% with capital expenditure at 0.3% of revenue. Every figure is computed directly from ADCT's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $81M | -149.3% | -175.3% |
| FY2024 | $71M | -184.4% | -222.8% |
| FY2023 | $69M | -240.4% | -347.6% |
| FY2022 | $75M | -164.7% | -209.8% |
How does ADCT compare against its actual peer set?
The full CompsDesk Peer Benchmark Pack: up to 14 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, provenance for every number, board-ready PDF + CSV. One-off $249.
Related in the same sector: ABBV · ABCL · ABT · ABUS · ACAD · ACNT
See ADCT benchmarked against two sector peers (free) →
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.